Common TitlePADDLE
Official Title Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study
Phase Phase IV
ClinicalTrials.gov NCT02211482
Treatments
Lamivudine
, Lamivudine
Tradename:EpivirOther Names:3TCClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Dolutegravir-Lamivudine
Dolutegravir-Lamivudine
Tradename:DovatoOther Names:DTG-3TCClass:Single-Tablet RegimensCategories Treatment-NaiveDual Therapy
Funding
IndustryViiV Healthcare
Non-IndustryThe Huesped Foundation
References
- Cahn P, Rolón MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017;20:21678.